Next date
None yet
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Actinic Keratosis of Face and Scalp
- Main trialPhase 3
- “The goal of this clinical trial is to show superiority of Veregen® 10% ointment to Placebo measured by complete (100%) clearance of a pre-defined treatment area (TA) following a treatment period of 12 weeks and a 4-weeks post-treatment (PT) period (i.e., after 16 weeks at most in patients without complete clearance at the end of the treatment (EoT) period).”In the company’s words, NCT07137819 on ClinicalTrials.gov
Other drugs for Actinic Keratosis of Face and Scalp
- Reformulated Levulan Kerastick containing aminolevulinic acid hydrochlorideSun Pharma · Phase 3
- HW211026Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Phase 2
- RLS-1496Rubedo Life Sciences, Inc. · Phase 1/2
- TirbanibulinAlmirall, S.A. · Marketed (Phase 4 trial)
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Mar 2026 | Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026